SOLACI-CACI 2021 Webinar | Challenges in TAVI – Severe CAD & Coronary Occlusion

Next Thursday, October 14, we will hold a joint event between SOLACI, CACI and the Microport company on “Challenges in TAVI: Severe Coronary Disease and Coronary Occlusion”. The activity is part of the satellite events of the SOLACI-CACI 2021 Congress and, as such, will have the participation of important international and Latin American speakers. Date:...

More Keys to Define Moderate Aortic Stenosis

Amidst the current efforts to prove early intervention might have benefits in moderate aortic stenosis (AS), this trial comes along directing us back to basics. In patients with symptomatic aortic stenosis, peaking mortality will clearly justify intervention. But what is the case when there are no symptoms? According to this recent analysis published in JAMA,...

Watch Again Advanced Strategias on Bifurcations Management in our Youtube Account

Watch Again “Advanced Strategias on Bifurcations Management” in our Youtube Account Program Provisional stent technique as a treatment philosophy: the step by step and when to use it. Critical analysis of the POT, Kissing, Re POT technique. Provisional strategy vs 2 stents in No ULM The case in which I require a second stent: when,...

The most read scientific papers of September in interventional cardiology

01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European...

TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors?

In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Cardiologists, hematologists, clinicians, and...